Quoin Pharmaceuticals (QNRX) Projected to Release Quarterly Earnings on Thursday

Quoin Pharmaceuticals (NASDAQ:QNRX) is expected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($1.5157) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 9:30 AM ET.

Quoin Pharmaceuticals (NASDAQ:QNRX) last released its quarterly earnings data on Friday, August 14th. The company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.61) by ($0.29).

Quoin Pharmaceuticals Price Performance

NASDAQ:QNRX traded up $0.15 on Tuesday, reaching $4.17. 8,089 shares of the company’s stock were exchanged, compared to its average volume of 268,666. The stock has a fifty day simple moving average of $5.40 and a 200-day simple moving average of $6.07. Quoin Pharmaceuticals has a 52 week low of $3.25 and a 52 week high of $23.50. The firm has a market cap of $20.03 million, a price-to-earnings ratio of -0.17 and a beta of 1.56.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Wall Street Zen raised shares of Quoin Pharmaceuticals to a “sell” rating in a report on Saturday, October 17th. Canaccord Genuity Group began coverage on shares of Quoin Pharmaceuticals in a report on Monday, October 19th. They set a “buy” rating and a $18.00 target price on the stock. Lake Street Capital began coverage on Quoin Pharmaceuticals in a research report on Wednesday, September 23rd. They set a “buy” rating and a $20.00 target price on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a report on Friday, October 16th. Finally, BTIG Research initiated coverage on Quoin Pharmaceuticals in a research report on Monday, October 12th. They issued a “buy” rating and a $14.00 price target for the company. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $17.33.

Insider Activity

In other news, COO Denise P. Carter bought 20,490 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The shares were acquired at an average price of $4.88 per share, with a total value of $99,991.20. Following the acquisition, the chief operating officer owned 37,709 shares of the company’s stock, valued at approximately $184,019.92. The trade was a 119.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Sally Lawlor bought 10,244 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The shares were purchased at an average cost of $4.88 per share, for a total transaction of $49,990.72. Following the acquisition, the chief financial officer directly owned 10,684 shares in the company, valued at $52,137.92. This trade represents a 2,328.18% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 57,370 shares of company stock valued at $279,966 over the last ninety days. 7.54% of the stock is owned by insiders.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd. is a clinical-stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases. The company is primarily pursuing therapies for conditions with significant unmet medical needs, including rare genetic disorders affecting the skin.

Quoin’s lead program is QRX003, a topical lotion being developed for Netherton syndrome, a rare inherited skin disorder associated with impaired skin-barrier function. The company is also developing QRX004, a topical product candidate intended for recessive dystrophic epidermolysis bullosa, a severe genetic skin disease.